-
Something wrong with this record ?
Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients
P. Kosztyu, M. Hill, J. Jemelkova, L. Czernekova, LR. Kafkova, M. Hruby, K. Matousovic, K. Vondrak, J. Zadrazil, I. Sterzl, J. Mestecky, M. Raska,
Language English Country Switzerland
Document type Journal Article
Grant support
NV15-33686A
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Directory of Open Access Journals
from 2013
Free Medical Journals
from 2010
ProQuest Central
from 1994-05-01 to 1 year ago
Open Access Digital Library
from 2013-01-01
Medline Complete (EBSCOhost)
from 2005-01-01
Health & Medicine (ProQuest)
from 1994-05-01 to 1 year ago
Karger Open Access
from 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1996
PubMed
29529610
DOI
10.1159/000487903
Knihovny.cz E-resources
- MeSH
- Glucocorticoids pharmacology therapeutic use MeSH
- Glycosylation drug effects MeSH
- Glomerulonephritis, IGA diagnosis drug therapy MeSH
- Immunoglobulin A blood immunology metabolism MeSH
- Antigen-Antibody Complex blood MeSH
- Humans MeSH
- Prednisone therapeutic use MeSH
- Prognosis MeSH
- Antibodies blood MeSH
- Case-Control Studies MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
BACKGROUND/AIMS: IgA nephropathy is associated with aberrant O-glycosylation of IgA1, which is recognized by autoantibodies leading to the formation of circulating immune complexes. Some of them, after deposition into kidney mesangium, trigger glomerular injury. In patients with active disease nonresponding to angiotensin-converting enzyme inhibitors or angiotensin II blockers, corticosteroids are recommended. METHODS: The relationship between the corticosteroid therapy and serum levels of IgA, aberrantly O-glycosylated IgA1, IgA-containing immune complexes and their mesangioproliferative activity was analyzed in IgA nephropathy patients and disease and healthy controls. RESULTS: Prednisone therapy significantly reduced proteinuria and levels of serum IgA, galactose-deficient IgA1, and IgA-IgG immune complexes in IgA nephropathy patients and thus reduced differences in all of the above parameters between IgAN patients and control groups. A moderate but not significant reduction of mesangioproliferative potential of IgA-IgG immune complexes and IgA sialylation was detected. CONCLUSION: The prednisone therapy reduces overall aberrancy in IgA1 O-glycosylation in IgA nephropathy patients, but the measurement of IgA1 parameters does not allow us to predict the prednisone therapy outcome in individual patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000873
- 003
- CZ-PrNML
- 005
- 20201113103044.0
- 007
- ta
- 008
- 190107s2018 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1159/000487903 $2 doi
- 035 __
- $a (PubMed)29529610
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kosztyu, Petr $7 xx0239748 $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University, Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
- 245 10
- $a Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients / $c P. Kosztyu, M. Hill, J. Jemelkova, L. Czernekova, LR. Kafkova, M. Hruby, K. Matousovic, K. Vondrak, J. Zadrazil, I. Sterzl, J. Mestecky, M. Raska,
- 520 9_
- $a BACKGROUND/AIMS: IgA nephropathy is associated with aberrant O-glycosylation of IgA1, which is recognized by autoantibodies leading to the formation of circulating immune complexes. Some of them, after deposition into kidney mesangium, trigger glomerular injury. In patients with active disease nonresponding to angiotensin-converting enzyme inhibitors or angiotensin II blockers, corticosteroids are recommended. METHODS: The relationship between the corticosteroid therapy and serum levels of IgA, aberrantly O-glycosylated IgA1, IgA-containing immune complexes and their mesangioproliferative activity was analyzed in IgA nephropathy patients and disease and healthy controls. RESULTS: Prednisone therapy significantly reduced proteinuria and levels of serum IgA, galactose-deficient IgA1, and IgA-IgG immune complexes in IgA nephropathy patients and thus reduced differences in all of the above parameters between IgAN patients and control groups. A moderate but not significant reduction of mesangioproliferative potential of IgA-IgG immune complexes and IgA sialylation was detected. CONCLUSION: The prednisone therapy reduces overall aberrancy in IgA1 O-glycosylation in IgA nephropathy patients, but the measurement of IgA1 parameters does not allow us to predict the prednisone therapy outcome in individual patients.
- 650 _2
- $a protilátky $x krev $7 D000906
- 650 _2
- $a imunokomplex $x krev $7 D000936
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a IgA nefropatie $x diagnóza $x farmakoterapie $7 D005922
- 650 _2
- $a glukokortikoidy $x farmakologie $x terapeutické užití $7 D005938
- 650 _2
- $a glykosylace $x účinky léků $7 D006031
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoglobulin A $x krev $x imunologie $x metabolismus $7 D007070
- 650 _2
- $a prednison $x terapeutické užití $7 D011241
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jemelková, Jana $7 xx0239842 $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University, Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.Republic.
- 700 1_
- $a Hill, Martin, $d 1962- $7 mzk2005304431 $u Department of Steroids and Proteohormones and Department of Clinical Immunology, Institute of Endocrinology, Prague, Czech
- 700 1_
- $a Czerneková, Lýdie $7 xx0239737 $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University, Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Kafkova, Leona Raskova $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University, Olomouc and University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Hruby, Miroslav $u Department of Internal Medicine III Nephrology, Rheumatology and Endocrinology, Palacky University Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Matousovic, Karel $u Department of Medicine, Second School of Medicine, Charles University, Prague and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Vondrak, Karel $u Department of Pediatrics, Second School of Medicine, Charles University, Prague and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Zadrazil, Josef $u Department of Internal Medicine III Nephrology, Rheumatology and Endocrinology, Palacky University Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Sterzl, Ivan $u Department of Steroids and Proteohormones and Department of Clinical Immunology, Institute of Endocrinology, Prague, Czech Republic.
- 700 1_
- $a Mestecky, Jiri $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Division of Immunology and Gnotobiology Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic. Institute of Immunology and Microbiology, First School of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Raska, Milan $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University, Olomouc and University Hospital Olomouc, Olomouc, Czech Republic. Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
- 773 0_
- $w MED00003064 $t Kidney & blood pressure research $x 1423-0143 $g Roč. 43, č. 2 (2018), s. 350-359
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29529610 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20201113103042 $b ABA008
- 999 __
- $a ok $b bmc $g 1364860 $s 1038996
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 43 $c 2 $d 350-359 $e 20180306 $i 1423-0143 $m Kidney & blood pressure research $n Kidney Blood Press Res $x MED00003064
- GRA __
- $a NV15-33686A $p MZ0
- LZP __
- $a Pubmed-20190107
